EduCap Oral Immunity to All COVID Versions Trained microRNA as an Immune USB Drive for T Cell killing and B Cell Antibody Production and Spin-Off Tech from This New Technology
The Sigma One protein is the master key that does not mutate, engineered by Dr. Lieber Ph.D. Chemist at Harvard for the 1,000 Talent Program of China, Wuhan and Dr. Fauci gain-of -function bioweapons research in association with USAMRID. EduCap simply incubates this portion of the Sigma one spike protein with a dendritic culture in a BioReactor to generate in 5 days about 45 pounds of microRNA exosomes. It generates many thousands of standard-sized Lonza oral capsules that protect the freeze-dried Exosome memory molecules microRNA immune USB drives to deliver these memory immune exosomes to the terminal end of the small bowel. The liposomes carry the exosomes to the splanchnic small bowel to liver and spleen and bone marrow. This information induction results in a nontoxic stimulation of T Cell Killing COVID to B Cell Immune tagging for killing COVID by activated macrophages. COVID viruses are carried in vesicular like a molecular bus, as dry viral particles cannot attach or infect anyone. The Chinese Wuhan lab had Dr. Lieber's Sigma One modified virus, so it currently cannot infect bats as tested recently. Gain of function by Dr. Barej Ph.D., U of NC Chapel Hill, working with Dr. Fauci and Wuhan, improved the transmission ability and toxicity by adding other genetic factors for gain-of-function toxicity as Schitin one genes etc. The Brisbane Austalia animal lab took the 1,000 miles from Wuhan bat virus and added 18 HIV AIDS genes, so that it could disrupt mitochondrial extracellular matrix electron transport, lowering ATP and NADH energy by hydroperoxyl radical oxidative free radicals, resulting in mitochondrial dysfunction and the hydroperoxyl radical crosslinks Von Willibrands clotting factor causing clots, anoxia, strokes, embolism and death in many cases. The high levels of free radicals attach to body proteins induction of autoimmunity and chromosome damage induction of cancer, and spongiform neural changes in the brain resulting in Scrapie or spongiform neural degeneration and death. The EduCap helps to stop all these potential situations, as those who have been vaccinated are a magnet to pick up the COVID variants. Utilizing my protocols of antioxidants and mitochondrial support stops the VaXXed person from generating new more lethal strains of the virus. This is accomplished with my proven use of First Line of Defense Protocols to kill the COVID virus and Vaccine Pre and Post Rescue Protocols rejuvenate mitochondria and genetics from my NutriMedical.com site.
Laboratory and imaging monitoring of a toxic individual mitochondrial function and organ especially brain imaging must be available to prove regression of toxic degeneration with EduCap plus my protocols. Great Plains lab OAT Organic Acids and MitoTOX panels can monitor improvement in vaXXed persons, along with Dr. Richard Fleming M.D. Ph.D. J.D. Nuclear Cardiologist imaging standardization to compare images A, B, C in time to prove that neural brain deterioration is now improving with the addition of EduCap, to block reinfection with future variant COVID strains.
This technology is simple memory microRNA exosome using a lock a key approach to generate massive memory molecules exosome microRNA, delivered by safe Lonza, patented technologies to prevent deterioration from stomach acid, Pepsin stomach enzymes. pancreatic digestive enzymes and deterioration from pathogen co-digestion. There are no toxins e.g. PEG now 73 percent of people are sensitive to this carrier. All mRNA and Johnson and Johnson double-stranded DNA vaccines generate Spike Protein genotoxic fake vaccines. These gene induction vaccines all create Spike Protein gain of function toxins causing vascular, immune, CNS injury and generating microRNA InfoToxins throwing off balanced genetic regulatory exosomes.
The Sigma One protein is the master key that does not mutate, engineered by Dr. Lieber Ph.D. Chemist at Harvard for the 1,000 Talent Program of China, Wuhan and Dr. Fauci gain-of -function bioweapons research in association with USAMRID. EduCap simply incubates this portion of the Sigma one spike protein with a dendritic culture in a BioReactor to generate in 5 days about 45 pounds of microRNA exosomes. It generates many thousands of standard-sized Lonza oral capsules that protect the freeze-dried Exosome memory molecules microRNA immune USB drives to deliver these memory immune exosomes to the terminal end of the small bowel. The liposomes carry the exosomes to the splanchnic small bowel to liver and spleen and bone marrow. This information induction results in a nontoxic stimulation of T Cell Killing COVID to B Cell Immune tagging for killing COVID by activated macrophages. COVID viruses are carried in vesicular like a molecular bus, as dry viral particles cannot attach or infect anyone. The Chinese Wuhan lab had Dr. Lieber's Sigma One modified virus, so it currently cannot infect bats as tested recently. Gain of function by Dr. Barej Ph.D., U of NC Chapel Hill, working with Dr. Fauci and Wuhan, improved the transmission ability and toxicity by adding other genetic factors for gain-of-function toxicity as Schitin one genes etc. The Brisbane Austalia animal lab took the 1,000 miles from Wuhan bat virus and added 18 HIV AIDS genes, so that it could disrupt mitochondrial extracellular matrix electron transport, lowering ATP and NADH energy by hydroperoxyl radical oxidative free radicals, resulting in mitochondrial dysfunction and the hydroperoxyl radical crosslinks Von Willibrands clotting factor causing clots, anoxia, strokes, embolism and death in many cases. The high levels of free radicals attach to body proteins induction of autoimmunity and chromosome damage induction of cancer, and spongiform neural changes in the brain resulting in Scrapie or spongiform neural degeneration and death. The EduCap helps to stop all these potential situations, as those who have been vaccinated are a magnet to pick up the COVID variants. Utilizing my protocols of antioxidants and mitochondrial support stops the VaXXed person from generating new more lethal strains of the virus. This is accomplished with my proven use of First Line of Defense Protocols to kill the COVID virus and Vaccine Pre and Post Rescue Protocols rejuvenate mitochondria and genetics from my NutriMedical.com site.
Laboratory and imaging monitoring of a toxic individual mitochondrial function and organ especially brain imaging must be available to prove regression of toxic degeneration with EduCap plus my protocols. Great Plains lab OAT Organic Acids and MitoTOX panels can monitor improvement in vaXXed persons, along with Dr. Richard Fleming M.D. Ph.D. J.D. Nuclear Cardiologist imaging standardization to compare images A, B, C in time to prove that neural brain deterioration is now improving with the addition of EduCap, to block reinfection with future variant COVID strains.
This technology is simple memory microRNA exosome using a lock a key approach to generate massive memory molecules exosome microRNA, delivered by safe Lonza, patented technologies to prevent deterioration from stomach acid, Pepsin stomach enzymes. pancreatic digestive enzymes and deterioration from pathogen co-digestion. There are no toxins e.g. PEG now 73 percent of people are sensitive to this carrier. All mRNA and Johnson and Johnson double-stranded DNA vaccines generate Spike Protein genotoxic fake vaccines. These gene induction vaccines all create Spike Protein gain of function toxins causing vascular, immune, CNS injury and generating microRNA InfoToxins throwing off balanced genetic regulatory exosomes.
The EduCap is simple immune induction by USB-type memory molecule gut transfer. EduCaps can eliminate the need for utilizing special versions of all vaccines, autoimmune disease, cancer removal by activated macrophages that promote health, and reverse gene silencing of the epigenome of aging. For Veterans and trauma victims, future potentials will result in potential limb or organ regeneration and age reversal. Veterinary medicine, military preparedness, animal and nature animal husbandry and elimination of toxic pesticides, and improved recovery of all types e.g. high valued race horses regeneration of joints, heart and neurological function. EduCap microRNA and my genetic scalar technology of gene induction of the hologram of life, can include my patented building blocks as a placenta equivalent Red Deer Velvet DR in a Lonza capsule to preserve molecular integrity. In combination with ethical stem cell harvesting and support. and the EduCap will slow and reverse aging for all citizens who partake. Civilians and military with improved mineralized and improved nutrition, can regenerate natural regenerative function organ technologies.
EduCap is the most important breakthrough of the 21st Century for all life forms on Earth, as microRNA exosomes are the regulates health and illness in all species on the planet. The value to society with a population that by the coming decades the emerging group will be the growth of alert healthy population that I call The Wellderly, who are capable of doing sports and activities beyond 100 and learning and business activities rather than nonproductive inactivity. I forsee many Regerantive Veterans that restore organs such as their kidneys, lungs, heart. limbs, to live full abundant lives. I see many veterans with restored organs and limbs, with future applications of this amazing technology.
Prophecies of our future in the Bible, we can see a day will come with the return of our King of Kings, when peoples of Earth will live renewed bodies to very advanced years healed from trauma, aging, and the ravages of time.
--
Dr Bill Deagle MD AAEM ACAM A4M ACOEM CIME AAFP CCFP TOX
EduCap is the most important breakthrough of the 21st Century for all life forms on Earth, as microRNA exosomes are the regulates health and illness in all species on the planet. The value to society with a population that by the coming decades the emerging group will be the growth of alert healthy population that I call The Wellderly, who are capable of doing sports and activities beyond 100 and learning and business activities rather than nonproductive inactivity. I forsee many Regerantive Veterans that restore organs such as their kidneys, lungs, heart. limbs, to live full abundant lives. I see many veterans with restored organs and limbs, with future applications of this amazing technology.
Prophecies of our future in the Bible, we can see a day will come with the return of our King of Kings, when peoples of Earth will live renewed bodies to very advanced years healed from trauma, aging, and the ravages of time.
--
Dr Bill Deagle MD AAEM ACAM A4M ACOEM CIME AAFP CCFP TOX
A NON-ANTIGENIC DENTRITIC microRNA EXOSOMAL BIOLOGIC FOR CONFERING T-CELL AND B-CELL IMMUNITY AGAINST ALL VARIANTS OF COVID-19
DETAILED DESCRIPTION
Broadly, the present invention provides a non-antigen vaccination composition, method, and system that embodies dendritic-derived exosomes resulting from the incubation of dendritic cells with the Spike Protein of COVID-19, the Spike Protein including an RBD portion that is common to ALL variants of COVID-19 in such a way that the dendritic cells process the Spike Protein of COVID-19 for presentation so as to enable immune education of naïve T-cells and B-cells. The exosomes derived from those incubated dendritic cells are harvested and encapsulated for oral delivery so as to be released within the terminal ileum having exosome receptor cells. The exosome receptor cells transfer the exosomes to the splanchnic circulation to the liver sinusoids, spleen, and bone marrow, thereby conferring an acquired immune response to the COVID-19 virus, and all variants thereof. Acquiring an immune response to the COVID-19 virus (or any variant), in the manner according to the invention, does not expose the person to the COVID-19 virus, or any dangerous antigens thereof.
The EduCaps™ of the invention do not cause the person’s cells to create Spike Proteins for immune education. Instead, EduCaps stimulates both cellular T-cell viral killing, and humoral B-cell viral identification immunity. By contrast, all known mRNA and DNA vaccines only generate partial B-cell viral identification (non-killing) immunity. For example, the partial B-cell viral immunity does not stop other sub-strains, such as the Delta variant and the Mu variant. Further, EduCap™ vaccination against COVID-19 does not create new viral strains that can evade EduCap™ immune identification and elimination. By contrast, known mRNA and DNA vaccines create new variants that selectively avoid the partial immunity provided by such vaccines.
EduCaps™ avoid the possibility of new pandemic viral emergencies, cytokine storms, mitochondria aerobic failure, serious illnesses, or death via variant strains of COVID-19. Thus, EduCaps™ provide a safe dendritic human universal non-antigenic encapsulated vaccine that transfers recognition of the immunogenic substance/virus to the human immune system.
The present invention blocks and terminates COVID-19 viruses (or variants) from attaching to the ACE2 receptor of the human Sigma One RBD antigen, thereby blocking viral entry into human cells by COVID-19 or any variant. Since the Sigma One RBD antigen is common to ALL COVID variants that can affect humans, EduCaps™ do not cause variants that can spread or become selectively dominant as a result of EduCap™ vaccination.
Broadly, the present invention provides a non-antigen vaccination composition, method, and system that embodies dendritic-derived exosomes resulting from the incubation of dendritic cells with the Spike Protein of COVID-19, the Spike Protein including an RBD portion that is common to ALL variants of COVID-19 in such a way that the dendritic cells process the Spike Protein of COVID-19 for presentation so as to enable immune education of naïve T-cells and B-cells. The exosomes derived from those incubated dendritic cells are harvested and encapsulated for oral delivery so as to be released within the terminal ileum having exosome receptor cells. The exosome receptor cells transfer the exosomes to the splanchnic circulation to the liver sinusoids, spleen, and bone marrow, thereby conferring an acquired immune response to the COVID-19 virus, and all variants thereof. Acquiring an immune response to the COVID-19 virus (or any variant), in the manner according to the invention, does not expose the person to the COVID-19 virus, or any dangerous antigens thereof.
The EduCaps™ of the invention do not cause the person’s cells to create Spike Proteins for immune education. Instead, EduCaps stimulates both cellular T-cell viral killing, and humoral B-cell viral identification immunity. By contrast, all known mRNA and DNA vaccines only generate partial B-cell viral identification (non-killing) immunity. For example, the partial B-cell viral immunity does not stop other sub-strains, such as the Delta variant and the Mu variant. Further, EduCap™ vaccination against COVID-19 does not create new viral strains that can evade EduCap™ immune identification and elimination. By contrast, known mRNA and DNA vaccines create new variants that selectively avoid the partial immunity provided by such vaccines.
EduCaps™ avoid the possibility of new pandemic viral emergencies, cytokine storms, mitochondria aerobic failure, serious illnesses, or death via variant strains of COVID-19. Thus, EduCaps™ provide a safe dendritic human universal non-antigenic encapsulated vaccine that transfers recognition of the immunogenic substance/virus to the human immune system.
The present invention blocks and terminates COVID-19 viruses (or variants) from attaching to the ACE2 receptor of the human Sigma One RBD antigen, thereby blocking viral entry into human cells by COVID-19 or any variant. Since the Sigma One RBD antigen is common to ALL COVID variants that can affect humans, EduCaps™ do not cause variants that can spread or become selectively dominant as a result of EduCap™ vaccination.
Referring now to FIGS 1 through 20, the present invention includes a method and system of programming immune memory molecules for whole body protection. The process incorporates the following steps: step 1, immune dendritic culture of Sigma One protein of COVID-19; step 2, exosome memory molecule extraction (five to seven days); step 3, protection of trained memory (solution of) exosomes Sigma One protein recognition - e.g., including freeze-drying exosomes and then enclosing them in Delayed Release oral capsules; step 4, taking the Delayed Release oral capsules (EduCaps™) via oral ingestion (stable at room temperature, taken with water, juice, or fluids) to be micellized at the terminal ileum and then absorbed for entry into the splanchnic circulation to the liver sinusoids, the spleen, and the bone marrow to train the T-cells and B-cells residing therein; and step 5, monitor blood immune T-cell cellular and B-cell immunoglobulin response in 4 to 6 weeks (including blood labs immunological assay) for verification of immune transfer memory effectuation. This educates the immune system, particularly, IgG4 T-cell virus killing and B-cell viral tagging lgM antibodies. By performing lab testing at two to four weeks after consuming the oral EduCaps™, detectable antibodies can be measured that indicate successful immune memory transfer. Immune memory transfer includes transfer of microRNA (miRNA) that contain information that enables lgG4 T-cell viral killing capacity, and B-cell viral identification capacity. This creates long term T-cell and B-cell immunity, thereby providing complete viral illness protection.
Antigen transfer to dendritic cells creates exosomes that educate the immune system to recognize COVID-19 and variants and to identify and kill the virus attaching to the ACE2 receptor.
Thus, immune memory molecules (microRNA) are contained within exosomes, which are dried and then encapsulated for pH protection from stomach acid and digestive enzymes (e.g., using Lonza Capsugel DR™ capusles). Dendritic exosomes transfer immune information to T-cells and B-cells throughout the body, thereby providing to the person consuming the EduCaps™ cellular and humoral immune protection from COVID-19, and all variants thereof.
The present invention can be manufactured using a bioreactor with standardized universal human dendritic cells, and standardized Spike Protein antigen for incubation therewith. The standardized universal human dendritic cells and Spike Protein together after 5-7 days of incubation, generate immune-training exosomes effective against COVID-19 and variants. The immune-training exosomes are then freeze-dried, and then encapsulated within Delayed Release Capsules (such as LONZA Capsugel DR capsules) without any binders or adjuvants, thereby providing oral EduCaps™. The oral EduCaps™ of the invention provide symptom-free induction of immunity to COVID-19 and all variants, without infection by COVID-19 or variants, and without symptoms of COVID-19 or variants.
A user can orally consume one EduCap™ capsule for each of seven days, with water or juice, thereby providing the user with immune education against COVID-19 or any variant thereof, without suffering any toxicity or side effects, and without experiencing any symptoms of COVID-19 or any variant thereof.
It should be understood, of course, that the foregoing relates to exemplary embodiments of the invention, and that modifications can be made without departing from the spirit and scope of the invention as set forth in the following claims.
CLAIMS
What is claimed is:
Antigen transfer to dendritic cells creates exosomes that educate the immune system to recognize COVID-19 and variants and to identify and kill the virus attaching to the ACE2 receptor.
Thus, immune memory molecules (microRNA) are contained within exosomes, which are dried and then encapsulated for pH protection from stomach acid and digestive enzymes (e.g., using Lonza Capsugel DR™ capusles). Dendritic exosomes transfer immune information to T-cells and B-cells throughout the body, thereby providing to the person consuming the EduCaps™ cellular and humoral immune protection from COVID-19, and all variants thereof.
The present invention can be manufactured using a bioreactor with standardized universal human dendritic cells, and standardized Spike Protein antigen for incubation therewith. The standardized universal human dendritic cells and Spike Protein together after 5-7 days of incubation, generate immune-training exosomes effective against COVID-19 and variants. The immune-training exosomes are then freeze-dried, and then encapsulated within Delayed Release Capsules (such as LONZA Capsugel DR capsules) without any binders or adjuvants, thereby providing oral EduCaps™. The oral EduCaps™ of the invention provide symptom-free induction of immunity to COVID-19 and all variants, without infection by COVID-19 or variants, and without symptoms of COVID-19 or variants.
A user can orally consume one EduCap™ capsule for each of seven days, with water or juice, thereby providing the user with immune education against COVID-19 or any variant thereof, without suffering any toxicity or side effects, and without experiencing any symptoms of COVID-19 or any variant thereof.
It should be understood, of course, that the foregoing relates to exemplary embodiments of the invention, and that modifications can be made without departing from the spirit and scope of the invention as set forth in the following claims.
CLAIMS
What is claimed is:
1. A method of vaccinating a person against COVID-19 and all variants thereof, the method comprising:
incubating a dendritic cell culture of a receptor binding domain of a Sigma One portion of a Spike Protein of a COVID-19 virus, or any variant of a COVID-19 virus;
separating a plurality of microRNA exosomes from the dendritic cell culture; and
administering the plurality of microRNA exosomes to the person, the plurality of microRNA exosomes conferring to the person T-cell and B-cell immunity against COVID-19 and all variants of COVID-19.
2. The method of claim 1, wherein the plurality of microRNA exosomes is encapsulated.
3. The method of claim 1, wherein administering the plurality of microRNA exosomes to the person includes encapsulating the plurality of microRNA exosomes in a delayed release capsule so as to target intestinal antigen-presenting cells in the terminal ileum.
4. A composition for vaccinating against a molecule-caused disease, the composition comprising: one or more dendritic-derived exosomes isolated from one or more dendritic cells incubated with an immunogenic substance associated with the molecule-caused disease.
ABSTRACT
A non-antigenic microRNA exosomal vaccination that includes dendritic-derived exosomes resulting from the incubation of dendritic cells with Spike Protein of a COVID-19 virus so that the dendritic cells process the Spike Protein of the COVID-19 virus to enable education of naïve T-cells. The exosomes so-derived are then harvested and encapsulated for delayed release oral capsule delivery to selectively reach intestinal antigen-presenting cells in the terminal ileum for stimulating an acquired immune response to the Spike Protein of the COVID-19 virus. The intestinal antigen-presenting cells incorporate the dendritic-derived exosomes, and thereby learn to recognize the Spike Protein as a threat, even though no dangerous antigens, RNA, or DNA modifications of the antigen or Spike Protein of the COVID-19 virus were introduced by the non-antigenic microRNA exosomal vaccine, thereby avoiding creation of new pandemic viral emergencies, cytokine storms, mitochondrial aerobic failure, serious illnesses, and death via mutated strains of the COVID-19 virus.
incubating a dendritic cell culture of a receptor binding domain of a Sigma One portion of a Spike Protein of a COVID-19 virus, or any variant of a COVID-19 virus;
separating a plurality of microRNA exosomes from the dendritic cell culture; and
administering the plurality of microRNA exosomes to the person, the plurality of microRNA exosomes conferring to the person T-cell and B-cell immunity against COVID-19 and all variants of COVID-19.
2. The method of claim 1, wherein the plurality of microRNA exosomes is encapsulated.
3. The method of claim 1, wherein administering the plurality of microRNA exosomes to the person includes encapsulating the plurality of microRNA exosomes in a delayed release capsule so as to target intestinal antigen-presenting cells in the terminal ileum.
4. A composition for vaccinating against a molecule-caused disease, the composition comprising: one or more dendritic-derived exosomes isolated from one or more dendritic cells incubated with an immunogenic substance associated with the molecule-caused disease.
ABSTRACT
A non-antigenic microRNA exosomal vaccination that includes dendritic-derived exosomes resulting from the incubation of dendritic cells with Spike Protein of a COVID-19 virus so that the dendritic cells process the Spike Protein of the COVID-19 virus to enable education of naïve T-cells. The exosomes so-derived are then harvested and encapsulated for delayed release oral capsule delivery to selectively reach intestinal antigen-presenting cells in the terminal ileum for stimulating an acquired immune response to the Spike Protein of the COVID-19 virus. The intestinal antigen-presenting cells incorporate the dendritic-derived exosomes, and thereby learn to recognize the Spike Protein as a threat, even though no dangerous antigens, RNA, or DNA modifications of the antigen or Spike Protein of the COVID-19 virus were introduced by the non-antigenic microRNA exosomal vaccine, thereby avoiding creation of new pandemic viral emergencies, cytokine storms, mitochondrial aerobic failure, serious illnesses, and death via mutated strains of the COVID-19 virus.
The account of the user that owns this channel has been inactive for the last 5 months. If it remains inactive in the next 28 days, that account will self-destruct and this channel may no longer have an owner.
The account of the user that owns this channel has been inactive for the last 5 months. If it remains inactive in the next 20 days, that account will self-destruct and this channel may no longer have an owner.